Payment overview · 2025
General Payments
$240.85
12 reported records · 6 companies
Healthcare provider profile · identity verified
Alexandre Alexeyenko, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LYNN, MA · NPI 1568464279
Verified facts
What the public records show
CMS Open Payments records show Alexandre Alexeyenko, M.D. received $240.85 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.98 | 28.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.86 | 24.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.58 | 20.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.40 | 15.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.36 | 7.2% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $12.67 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.85 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $72.86 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.58 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $12.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 306 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
103 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
166 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1736 | 227 |
| Metoprolol Succinate | Metoprolol Succinate | 1275 | 171 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1238 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 965 | 135 |
| Lisinopril | Lisinopril | 681 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 668 | 81 |
| Omeprazole | Omeprazole | 653 | 94 |
| Metformin Hcl | Metformin Hcl | 551 | 77 |
| Sertraline Hcl | Sertraline Hcl | 527 | 72 |
| Losartan Potassium | Losartan Potassium | 406 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 350 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 341 | 47 |
| Gabapentin | Gabapentin | 330 | 60 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 314 | 56 |
| Torsemide | Torsemide | 308 | 51 |
| Jardiance | Empagliflozin | 306 | 43 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 274 | 39 |
| Nortriptyline Hcl | Nortriptyline Hcl | 264 | 42 |
| Eliquis | Apixaban | 259 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 250 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 48 |
| Mirtazapine | Mirtazapine | 237 | 34 |
| Nifedipine Er | Nifedipine | 236 | 31 |
| Carvedilol | Carvedilol | 227 | 31 |
| Alendronate Sodium | Alendronate Sodium | 211 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 211 | 69 |
| Atenolol | Atenolol | 209 | 29 |
| Chlorthalidone | Chlorthalidone | 206 | 30 |
| Spironolactone | Spironolactone | 185 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 171 | 19 |
| Allopurinol | Allopurinol | 169 | 27 |
| Trulicity | Dulaglutide | 166 | 26 |
| Furosemide | Furosemide | 165 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 165 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 19 |
| Donepezil Hcl | Donepezil Hcl | 158 | 25 |
| Metformin Hcl Er | Metformin Hcl | 157 | 19 |
| Xarelto | Rivaroxaban | 156 | 21 |
| Trazodone Hcl | Trazodone Hcl | 153 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 142 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 140 | 21 |
| Ezetimibe | Ezetimibe | 137 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 130 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 43 |
| Famotidine | Famotidine | 124 | 20 |
| Ammonium Lactate | Ammonium Lactate | 112 | 34 |
| Labetalol Hcl | Labetalol Hcl | 109 | 18 |
| Farxiga | Dapagliflozin Propanediol | 103 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 100 | 16 |
| Finasteride | Finasteride | 98 | 15 |
| Warfarin Sodium | Warfarin Sodium | 94 | 11 |
| Glipizide Er | Glipizide | 93 | suppressed |
| Ketoconazole | Ketoconazole | 89 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 89 | 13 |
| Linzess | Linaclotide | 87 | 14 |
| Januvia | Sitagliptin Phosphate | 86 | 11 |
| Potassium Chloride | Potassium Chloride | 86 | 15 |
| Ozempic | Semaglutide | 82 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 12 |
| Tradjenta | Linagliptin | 80 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | suppressed |
| Nitroglycerin | Nitroglycerin | 75 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 74 | 25 |
| Loperamide | Loperamide Hcl | 74 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 16 |
| Lorazepam | Lorazepam | 73 | 19 |
| Meclizine Hcl | Meclizine Hcl | 73 | 17 |
| Creon | Lipase/Protease/Amylase | 68 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 67 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 65 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Vascepa | Icosapent Ethyl | 63 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 62 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 56 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Latanoprost | Latanoprost | 52 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 11 |
| Glipizide | Glipizide | 50 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 48 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 22 |
| Cefuroxime | Cefuroxime Axetil | 45 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Nadolol | Nadolol | 44 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 42 | 16 |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 11 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Nystatin | Nystatin | 39 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 38 | suppressed |
| Timolol Maleate | Timolol Maleate | 38 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Mirabegron Er | Mirabegron | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 25 | suppressed |
| Crestor | Rosuvastatin Calcium | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Nystop | Nystatin | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 14 |
| Prednisone | Prednisone | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.85 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, Fibroscan, JARDIANCE, MOUNJARO, Ozempic, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error